Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study

JBMR Plus - Tập 5 Số 7 - 2021
Christian Roux1,2, Thierry Thomas3,4, Julien Paccou5, Geoffray Bizouard6, Anne Crochard7, Emese Tóth7, Magali Lemaître6, F. Maurel6, L. Perrin7, Florence Tubach8,9
1Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
2Service de rhumatologie [CHU Cochin]
3Biologie Intégrative du Tissu Osseux
4Service de Rhumatologie [CHU Saint-Etienne]
5Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490
6IQVIA
7UCB Pharma S.A.[Braine-l'Alleud]
8CHU Pitié-Salpêtrière [AP-HP]
9Institut Pierre Louis d'Epidémiologie et de Santé Publique

Tóm tắt

ABSTRACTSevere osteoporotic fractures (hip, proximal humerus, pelvic, vertebral and multiple rib fractures) carry an increased risk of mortality. This retrospective cohort study in the French national healthcare database aimed to estimate refracture and mortality rates after severe osteoporotic fractures at different sites, and to identify mortality‐related variables. A total of 356,895 patients hospitalized for severe osteoporotic fracture between 2009 and 2014 inclusive were analyzed. The cohort was followed for 2 to 8 years up to the study end or until the patient died. Data were extracted on subsequent hospitalizations, refracture events, treatments, comorbidities of interest and survival. Time to refracture and survival were described using Kaplan‐Meier analysis by site of fracture and overall. Mortality risk factors were identified using a Cox model. Hip fractures accounted for 60.4% of the sample (N = 215,672). In the 12 months following fracture, 58,220 patients (16.7%) received a specific osteoporosis treatment, of whom 21,228 were previously treatment‐naïve. The 12‐month refracture rate was 6.3% (95% confidence interval [CI], 6.2%–6.3%), ranging from 4.0% (95% CI, 3.7%–4.3%) for multiple rib fractures to 7.8% (95% CI, 7.5%–8.1%) for pelvic fractures. Twelve‐month all‐cause mortality was 12.8% (95% CI, 12.7%–12.9%), ranging from 5.0% (95% CI, 4.7%–5.2%) for vertebral fractures to 16.6% (95% CI, 16.4%–16.7%) for hip fractures. Osteoporosis‐related mortality risk factors included fracture site, previous osteoporotic fracture (hazard ratio 1.21; 95% CI, 1.18–1.23), hip refracture (1.74; 95% CI, 1.71–1.77), and no prior osteoporosis treatment (1.24; 95% CI, 1.22–1.26). Comorbid cancer (3.15; 95% CI, 3.09–3.21) and liver disease (2.54; 95% CI, 2.40–2.68) were also strongly associated with mortality. In conclusion, severe osteoporotic fractures, including certain non‐hip nonvertebral fractures, carry a high burden in terms of mortality and refracture risk. However, most patients received no anti‐osteoporotic treatment. The findings emphasize the importance of better management of patients with severe fractures, and of developing effective strategies to reduce fracture risk in patients with osteoporosis. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Từ khóa


Tài liệu tham khảo

10.1186/s12877-016-0332-0

10.1007/s00198-016-3648-x

10.1016/S8756-3282(02)00787-1

10.1001/jama.2009.50

10.1111/1753-6405.12381

10.1016/S0140-6736(18)32112-3

10.7326/0003-4819-150-10-200905190-00005

10.1210/jc.2017-02656

10.1002/jbmr.3118

10.1007/s00198-012-2225-1

10.1002/jbmr.2393

10.1359/jbmr.2000.15.4.721

10.1007/s00198-017-3976-5

10.1007/s00198-018-4502-0

10.1007/s00198-018-4732-1

10.1007/s00198-019-04852-8

10.1007/s00198-019-05174-5

10.1002/jbmr.3953

10.1002/jbmr.3827

10.1007/s00198-018-4704-5

10.1016/j.jbspin.2018.02.009

10.1007/s00198-020-05557-z

10.1007/s11657-020-0706-y

10.1002/pds.4233

10.1016/j.respe.2017.05.004

10.1097/MLR.0000000000000471

Institut National de la Statistique et des Etudes Economiques. Bilan démographique 2017. 2018.https://www.insee.fr/fr/statistiques/3311422?sommaire=3311425. Accessed 6 May 2021.

10.1001/jama.2009.1462

Teng GG, 2008, Mortality and osteoporotic fractures: is the link causal, and is it modifiable?, Clin Exp Rheumatol, 26, S125

10.1007/s00198-011-1630-1

10.1007/s11914-017-0352-5

10.1007/s12178-012-9128-9

10.1007/s00198-012-1935-8

10.1002/jbmr.3374

10.1016/j.injury.2018.09.017

10.1007/s11657-020-0689-8

10.3928/01477447-20130523-21

10.1093/ageing/afu123

10.1136/bmj.c1069

10.1016/j.bone.2018.08.016

10.1007/s00198-005-1887-3

10.1007/s00198-011-1757-0

10.1002/jbmr.1968

10.1056/NEJMoa074941

Geel T, 2018, Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study, PLoS One, 13, e0198006, 10.1371/journal.pone.0198006

10.2147/CLEP.S168237

10.1016/j.jhep.2018.04.002

10.1007/s00198-007-0403-3

10.1007/s00198-017-3926-2

10.1016/j.beem.2008.06.001

10.1093/ageing/afp221

10.1186/s13018-019-1226-6

10.1111/jgs.15207

10.1007/s11657-019-0674-2

10.1016/j.jbspin.2008.10.008

Thông tin
Thông tin xuất bản

JBMR Plus

Tập 5 Số 7

Thông tin tác giả